AUS
NZ
UK
CA
USA
FRA
GER
ESP
ITA
NLD
PRT
SWE
GRC
IND
POL
BRA
ZAF
RUS
CHN
UAE
Highlight
- Zivo Biosciences Inc (Nasdaq:ZIVO) stocks soared by 74.78% on Thursday.
- Cellect Biotechnology Ltd (Nasdaq:APOP) stock fell 20.712% at 1 pm ET.
- vTv Therapeutics Inc. (Nasdaq:VTVT) stock rose 4.52 percent a day after the company announced that its psoriasis medicine showed positive results.
Zivo Biosciences Inc (Nasdaq:ZIVO) stock jumped more than 74%, while Cellect Biotechnology Ltd (Nasdaq:APOP) stock fell 20% on Thursday after the stocks drew massive interest from traders in intraday trading.
On the other hand, vTv Therapeutics Inc. (Nasdaq:VTVT) stock rose by 4.52 percent a day after the company announced that its psoriasis medicine HPP737 showed favorable results.
The following are some of the recent developments of the companies.
Zivo Biosciences Inc
Zivo is a technology-based research company based in the US and develops food products from algae. ZIVO started trading on Nasdaq on June 2. Its offering price was US$5 per share.
The ZIVO stock skyrocketed by 74.78 percent to US$6.03 at 12.52 pm ET for no apparent reason. However, traders may have been drawn by its low price, triggering a stock rally.
It saw a record trading volume, with over 52 million ZIVO shares exchanging hands. The company’s daily average trading volume is 2.2 million.
Its shares had jumped by 84 percent in the morning session.
Zivo has a market capitalization of US$55 million. Its 52-week highest and lowest stock prices were US$7.90 and US$2.72, respectively.
Also read: Earnings Alert: Accenture (ACN), Nike (NKE) post strong revenue growth
Copyright ©Kalkine Media 2021
Cellect Biotechnology Ltd
The Cellect stock fell 20.71 percent to US$19.0287 at 1 pm ET on September 24, again for no apparent reason. The company has a market capitalization of US$18 million. The highest and lowest stock prices for the last 52 weeks were US$35.52 and US$6.60, respectively.
The company’s total loss in Q2, 2021, was US$1.7 million or US$0.04 per share, compared to a loss of US$2.7 million, or US$0.07 per share, in Q2, 2020.
The expenses for research and development for the quarter were US$0.42 million compared to US$0.42 million in Q2, 2020.
General and administrative expenses were US$0.86 million against US$0.65 million in Q2, 2020. Finance expenses were US$0.43 million against US$1.63 million in Q2, 2020.
vTv Therapeutics Inc.
The VTVT stock rose by 4.52 percent to US$1.85 at 1.22 pm ET on September 24. The stocks soared a day after the company announced that its medicine HPP737 for treating severe psoriasis had shown favorable results.
The market capitalization of the company is US$153 million. The highest and lowest stock prices of VTVT for the last 52 weeks were US$4.75 and US$1.44, respectively.
The company reported revenue of US$1 million in Q1, 2021. The net loss for the period was US$5.9 million, or US$0.08 per share, compared to US$1.6 million, or US$0.02 in Q4, 2020.
Bottomline
Over the past year, the healthcare sector has shown considerable growth, boosted by robust sales, drug development, and faster approval, especially for covid vaccines. Industry experts believe the sector to continue that momentum in the coming quarters. But investors should evaluate the companies carefully before investing.
